Search

Researchers at MSK have been at the forefront of developing new treatments for advanced melanoma for many years. Learn more about the latest therapies.

… Monday, July 8, 2024 In recent years, advanced melanoma (a type of skin cancer) has been transformed from a disease that was almost always fatal to one that often can be brought under control for years, or even cured. Thanks to new drugs, people with advanced disease have a five-year survival rate of

Learn from neurosurgeon Viviane Tabar about the standard treatment for glioblastoma, which involves surgery, chemotherapy, and radiation.

… Saturday, August 25, 2018 Summary The passing of Senator John McCain has focused attention on the aggressive brain cancer called glioblastoma. Viviane Tabar, Chief of Neurosurgery, explains how the disease develops and how MSK treats people with glioblastoma and other brain cancers. Editor’s Note: This

State-of-the-art facility will be reduced by 76 feet while continuing to meet increasing demand for cancer care.

… Friday, May 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced an updated design for MSK’s forthcoming Kenneth C. Griffin Pavilion at MSK, which includes a reduction in the originally proposed height of the building by 76 feet. The newly-designed Griffin Pavilion, slated for construction

Learn about the latest advances in lung cancer treatment at MSK.

… Friday, November 15, 2024 Lung cancer is the second-most common cancer and remains the leading cause of cancer death in the United States. But a variety of new treatments, many of them developed or tested at Memorial Sloan Kettering Cancer Center (MSK), are helping to bring down the number of deaths.

Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.

… Friday, November 15, 2024 El cáncer pulmonar es el segundo cáncer más común y sigue siendo la principal causa de muerte por cáncer en los Estados Unidos. Sin embargo, una variedad de nuevos tratamientos, muchos de ellos desarrollados o probados en el Memorial Sloan Kettering Cancer Center (MSK), están

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

… Saturday, January 1, 2011 Summary To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. The goal of the new

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

… Thursday, September 11, 2025 A high-intensity radiation beam that penetrates the body to burn away tumors has been a standard weapon against cancer for more than a century. Over the years, radiation therapy has improved dramatically, but its effectiveness against cancers in multiple places can be limited

The July 22 MSK Science Spotlight features Luis Diaz, MD, Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.”

… Wednesday, July 22, 2020 The July 22 MSK Science Spotlight features Luis Diaz, MD , Head of the Division of Solid Tumor Oncology and Grayer Family Chair, presenting his work on ”Immunotherapy of Mismatch Repair Deficient Tumors.” An accomplished physician, pioneering researcher, and leader in the field

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

… Wednesday, March 8, 2023 You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

… Monday, October 8, 2012 Summary Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells. For the first time, a team of Memorial Sloan Kettering investigators has synthesized erythropoietin (also known as EPO), the hormone